BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 7737909)

  • 1. Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer.
    Naitoh H; Eguchi Y; Ueyama H; Kodama M; Hattori T
    Jpn J Cancer Res; 1995 Jan; 86(1):48-56. PubMed ID: 7737909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
    Nagayama M; Sato A; Hayakawa H; Urano T; Takada Y; Takada A
    Cancer; 1994 Mar; 73(5):1398-405. PubMed ID: 8111706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical demonstration of the plasminogen activator system in human gingival tissues and gingival fibroblasts.
    Xiao Y; Bunn CL; Bartold PM
    J Periodontal Res; 1998 Jan; 33(1):17-26. PubMed ID: 9524317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues.
    Umeda T; Eguchi Y; Okino K; Kodama M; Hattori T
    J Pathol; 1997 Dec; 183(4):388-97. PubMed ID: 9496254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization.
    Zheng MH; Fan Y; Panicker A; Smith A; Robertson T; Wysocki S; Robbins P; Papadimitriou JM; Wood DJ
    Am J Pathol; 1995 Dec; 147(6):1559-66. PubMed ID: 7495280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.
    Christensen L; Wiborg Simonsen AC; Heegaard CW; Moestrup SK; Andersen JA; Andreasen PA
    Int J Cancer; 1996 May; 66(4):441-52. PubMed ID: 8635858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression.
    Robert C; Bolon I; Gazzeri S; Veyrenc S; Brambilla C; Brambilla E
    Clin Cancer Res; 1999 Aug; 5(8):2094-102. PubMed ID: 10473092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
    Shiomi H; Eguchi Y; Tani T; Kodama M; Hattori T
    Am J Pathol; 2000 Feb; 156(2):567-75. PubMed ID: 10666386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
    Kim SJ; Shiba E; Kobayashi T; Yayoi E; Furukawa J; Takatsuka Y; Shin E; Koyama H; Inaji H; Takai S
    Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expression of plasminogen activator system in a rat model of periodontal wound healing.
    Xiao Y; Li H; Bunn C; Bartold PM
    J Periodontol; 2001 Jul; 72(7):849-57. PubMed ID: 11495131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study.
    Takeuchi Y; Nakao A; Harada A; Nonami T; Fukatsu T; Takagi H
    Am J Gastroenterol; 1993 Nov; 88(11):1928-33. PubMed ID: 8237943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer.
    Ito H; Yonemura Y; Fujita H; Tsuchihara K; Kawamura T; Nojima N; Fujimura T; Nose H; Endo Y; Sasaki T
    Virchows Arch; 1996 Feb; 427(5):487-96. PubMed ID: 8624578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of urokinase-type plasminogen activator receptor and plasminogen activator inhibitor-1 in gastric cancer.
    Kawasaki K; Hayashi Y; Wang Y; Suzuki S; Morita Y; Nakamura T; Narita K; Doe W; Itoh H; Kuroda Y
    J Gastroenterol Hepatol; 1998 Sep; 13(9):936-44. PubMed ID: 9794194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney.
    Xu Y; Hagege J; Mougenot B; Sraer JD; Rønne E; Rondeau E
    Kidney Int; 1996 Dec; 50(6):2011-9. PubMed ID: 8943484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tumor-associated prognostic factors of the plasminogen activator family: determination and clinical value of u-PA, t-PA, PAI-1, and PAI-2].
    Mengele K; Harbeck N; Reuning U; Magdolen V; Schmitt M
    Hamostaseologie; 2005 Aug; 25(3):301-10. PubMed ID: 16113755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasminogen activator inhibitor 2 and urokinase-type plasminogen activator in plasma and leucocytes in patients with severe sepsis.
    Robbie LA; Dummer S; Booth NA; Adey GD; Bennett B
    Br J Haematol; 2000 May; 109(2):342-8. PubMed ID: 10848822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urokinase, tissue-type plasminogen activator and plasminogen activator inhibitor-1 expression in severely stenosed and occluded vein grafts with thrombosis.
    Sirén V; Kauhanen P; Carpén O; Luther M; Lepäntalo M; Vaheri A; Lassila R
    Blood Coagul Fibrinolysis; 2003 Jun; 14(4):369-77. PubMed ID: 12945879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
    Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
    Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors involved in the plasminogen activation system in human breast tumours.
    Damjanovich L; Turzó C; Adány R
    Thromb Haemost; 1994 Jun; 71(6):684-91. PubMed ID: 7974332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.
    Nishikawa M; Stapleton PP; Freeman TA; Gaughan JP; Matsuda T; Daly JM
    J Am Coll Surg; 2004 Sep; 199(3):428-35. PubMed ID: 15325613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.